New techniques in RNA engineering promise longer-lasting therapies

New methods to shape RNA molecules into circles could lead to more effective and long-lasting therapies, shows a study by researchers at the University of California San Diego.

As digital health unicorns are pressured to do more with less, Transcarent gets a fresh $126M

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Transcarent’s $126 million Series D round, which

May 8, 2024

Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1

October 23, 2024

Home blood pressure machines are often wrong. The FDA must speak up

Hypertension is considered to be the No. 1 risk factor for death globally. So it’s no wonder convenient, relatively low-cost blood pressure machines with single-size,

August 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.